Catalog No.
Product Name
Application
Product Information
Citations
-
BCL6 Ligand
BCL6 ligand-4 is a selective ligand targeting BCL6, a key regulator of oncogenic transcription. This compound is primarily utilized in the synthesis of PROTACs, enabling targeted protein degradation for therapeutic applications in oncology research. BCL6 ligand-4 provides researchers with essential tools to explore BCL6-related pathways and develop innovative cancer treatments. -
BCL6 Inhibitor
SMRT peptide is a BCL6 inhibitor that functions by binding to the BTB domain of BCL6, thereby enhancing its transcriptional repression activity. This compound serves as a valuable tool for studying protein-protein interactions related to BCL6 function in various biological processes. Research applications include investigations into the role of BCL6 in cancer and other diseases where transcriptional regulation is critical. -
BCL6 Ligand
BCL6 ligand-5 is a selective ligand for the BCL6 protein, involved in transcriptional regulation and oncogenesis. This compound serves as a crucial component for the development of PROTAC-based degraders targeting BCL6, such as PROTAC BCL6 Degrader-2. Additionally, BCL6 ligand-5 has applications in tumor research, contributing to the study of cancer biology and therapeutic strategies. -
BCL6
OICR11029 is a selective inhibitor of BCL6, a transcriptional repressor implicated in various cancers. This compound demonstrates significant efficacy in disrupting BCL6 function, making it a valuable tool for investigating its role in tumorigenesis. OICR11029 is particularly useful for research focused on lymphoma and related hematological malignancies. -
Anti-CD19/CD3ε/Albumin Antibody
Faziprumig is a monoclonal antibody that targets CD19, CD3ε, and human serum albumin, exhibiting dissociation constants (Kd) of 0.0738 nM, 7.997 nM, and 0.6 nM, respectively. This reagent effectively activates T cells, leading to their lysis, and demonstrates significant efficacy in targeting and eliminating B-cell malignancies with low CD19 expression. Faziprumig is particularly relevant in the research of non-Hodgkin's lymphoma and various B-cell malignancies. -
CD19/4-1BB Antibody
Englumafusp alfa is a CD19/4-1BB antibody construct designed to enhance immune response by promoting CD19-specific cross-linking of the 4-1BB receptor on T and NK cells. This fusion protein consists of a CD19-specific antibody domain linked to trimerized extracellular domains of human 4-1BB ligand (41BBL). Its key biological activity supports investigations into immuno-oncology applications, particularly in targeting CD19-positive malignancies. Researchers can utilize Englumafusp alfa to study T cell activation and proliferation in the context of cancer therapies. -
Anti-CD19 Monoclonal Antibody
GBR-401 is a humanized anti-CD19 monoclonal antibody that targets CD19 with high affinity for FcγRIIIa. It exhibits potent cytotoxic activity against B-cell malignancies through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and direct cell killing. GBR-401 is effective in depleting malignant B cells and has been shown to prolong survival in various xenograft models using severe combined immunodeficiency (SCID) mice, making it a valuable tool for cancer research and therapeutic development. -
CD2 mAb
BTI-322 is a human IgG1κ monoclonal antibody targeting the CD2 antigen expressed on T cells and natural killer (NK) cells. This reagent demonstrates potent immunosuppressive activity by effectively inhibiting T cell proliferation in response to alloantigens in vitro. BTI-322 is known to recognize a majority of E-rosette-forming peripheral blood lymphocytes and T-cell leukemias, making it suitable for applications in research on renal allograft rejection and steroid-refractory acute graft-versus-host disease. Additionally, BTI-322 serves as a valuable tool for T-cell depletion studies in various immunological contexts. -
Anti-MS4A1/CD20 Monoclonal Antibody
Blidarvetug is a monoclonal antibody that targets MS4A1/CD20, specifically designed for veterinary applications. This reagent is utilized in the investigation of CD20-positive B-cell lymphoma in canine models, facilitating research into the pathophysiology and treatment strategies for this particular type of cancer. Its specificity for CD20 offers valuable insights into B-cell malignancies in veterinary oncology. -
CD20xCD3 Antibody
Imvotamab is a bispecific immunoglobulin M (IgM) antibody targeting CD20 and CD3. It induces T cell activation while preventing excessive stimulation and potential down-regulation of immune responses. This dual-action mechanism makes Imvotamab a valuable tool for research on B-cell malignancies, including multiple myeloma and non-Hodgkin's lymphoma, facilitating studies on immune modulation and therapeutic interventions. -
Anti-CD20 Antibody
BLX-301 is a humanized monoclonal antibody that targets CD20 on B cells. It demonstrates robust anti-tumor activity, making it a valuable tool for research in non-Hodgkin lymphoma and rheumatoid arthritis. This reagent can help elucidate mechanisms of B cell-mediated diseases and contribute to developing targeted therapies. -
Anti-CD79B/CD3E/MS4A1 Antibody
Anafiltamig is a trivalent monoclonal antibody that targets CD79B, CD3E, and MS4A1. This innovative reagent features a humanized IgG1κ anti-CD79B component combined with a bispecific scFv fragment designed to engage CD3E and MS4A1. By simultaneously bridging T and B cells, Anafiltamig activates T cells, leading to the selective elimination of B cell tumors. This compound is particularly useful for research in B cell malignancies, including non-Hodgkin lymphoma. -
CD22 Inhibitor
GSC-718 is a synthetic sialoside and a potent inhibitor of CD22, exhibiting an IC50 value of 0.161 μM for mouse CD22. This compound is known to promote the proliferation of B cells and enhance antibody production. GSC-718 is particularly relevant for research applications involving B-cell lymphoma and autoimmune conditions such as rheumatoid arthritis. -
Anti-CD22 Antibody
RFB4 is an anti-CD22 monoclonal antibody that specifically targets the CD22 antigen, a marker commonly expressed on B-cell malignancies. This antibody can be utilized to generate recombinant immunotoxins by fusing with the pseudomonas exotoxin PE38 through disulfide linkages, such as in the construct RFB4(dsFv)-PE38. RFB4 serves as a vital tool for research focused on cancer, particularly in studies related to lymphoma and other B-cell related diseases. -
CD22 Ligand
CD22 ligand-1 is a potent and selective ligand for CD22, exhibiting a binding affinity (KD) of 0.335 µM for human CD22 and 30.7 µM for myelin-associated glycoprotein (MAG). This compound facilitates the investigation of CD22-mediated signaling pathways and holds potential for advancing research in B-cell related diseases, including autoimmune disorders and lymphomas. Its high specificity for CD22 makes it a valuable tool for understanding the role of this receptor in immunological responses. -
CD276 Monoclonal Antibody
Elfetabart is a humanized monoclonal antibody that specifically targets CD276, exhibiting notable antitumor activity. This antibody belongs to the IgG1κ isotype, making it suitable for various applications in cancer research and therapeutic development. Its interaction with CD276 plays a critical role in modulating immune responses in the tumor microenvironment, thus making it a valuable tool for studying immune evasion and developing immunotherapeutic strategies. -
CD28-B7 Inhibitor
CD28-IN-2 is a selective inhibitor of the CD28-B7 interaction, demonstrating an IC50 of 22.4 μM and a Kd value of 24.1 μM. This compound effectively inhibits CD28-mediated immune activation and prevents T cell costimulation. CD28-IN-2 serves as a valuable tool in research investigating antitumor immunity and various immune-related disorders. -
CD272 Antibody Inhibitor
Radanstobart is a humanized monoclonal antibody that selectively inhibits CD272, a checkpoint protein involved in immune regulation. This antibody exhibits significant antitumor activity, making it valuable for cancer research and immunotherapy studies. It is classified as a human IgG4κ isotype, providing a robust platform for investigating immune responses and potential therapeutic approaches targeting the tumor microenvironment. -
ICOS/CD28 Antagonist
Acazicolcept is an Fc fusion protein that serves as a dual antagonist of the inducible T cell costimulator (ICOS) and CD28. This reagent exhibits significant anti-inflammatory activity, making it valuable for research in autoimmune disorders and T cell modulation. Its unique mechanism of action positions Acazicolcept as a key tool in studying the regulation of immune responses and potential therapeutic interventions. -
B7.1-CD28 Interaction Inhibitor
B7/CD28 Interaction Inhibitor 1 is a selective inhibitor of the B7.1-CD28 interaction, exhibiting an IC50 of 50 nM. This compound disrupts T-cell costimulation, making it a valuable tool for research in immunology and cancer therapy. Its ability to modulate T-cell responses highlights its potential applications in studying immune regulation and developing immunotherapeutic strategies. -
CD28 Inhibitor
DDS5 is a selective CD28 inhibitor with an affinity (kd) of 175.57 µM, effectively disrupting the CD28-CD80 interaction with an IC50 value of 332 µM. This compound is instrumental in researching immune-mediated diseases, including inflammatory bowel disease and rheumatoid arthritis, enabling investigations into immune response modulation and therapeutic strategies. -
Bioactive Peptide
CFP10 (71–85) is a bioactive peptide that stimulates the production of interferon-gamma (IFN-γ) and enhances cytotoxic T lymphocyte (CTL) activity in both CD4+ and CD8+ T cells. It is particularly effective in individuals expressing various MHC class II and class I molecules. This peptide is valuable for research applications focused on immune response modulation and T cell activation. -
EpCAM/CD3 Bispecific Antibody
M701 is a bispecific humanized antibody that targets epithelial cell adhesion molecule (EpCAM) and cluster of differentiation 3 (CD3). By binding to EpCAM on tumor cells and CD3 on T cells, M701 effectively links these two cell populations, facilitating targeted cytotoxicity and enhancing T cell-mediated immune responses. This reagent is particularly valuable for research focused on advanced epithelial solid tumors, aiding in the development of innovative therapies. -
Anti-CD3E Antibody
Ebribafusp alfa is an anti-CD3E IgG4κ chimeric antibody designed to modulate immune responses by targeting the CD3 epsilon subunit of the T cell receptor complex. This compound exhibits potential therapeutic activity in autoimmune diseases and T cell-related conditions by enhancing T cell-mediated immunity. Research applications include investigations into T cell activation and modulation strategies in immunotherapy and transplant biology. -
Anti-CD3E/CD4 Antibody
Amtabafusp alfa is a humanized IgG1 λ1 antibody that targets CD3E and CD4. This recombinant antibody is designed for applications in immunology and cancer research, facilitating the study of T cell activation and tumor microenvironment interactions. It serves as a crucial tool for investigating immune responses and therapeutic strategies in various diseases. -
Anti-FOLH1/PSMA And CD3E Antibody
Olsutamig is a bivalent humanized IgG4κ monoclonal antibody that targets FOLH1/PSMA and CD3E. This reagent effectively binds to the prostate-specific membrane antigen (PSMA) on tumor cells and to CD3E on T cells, leading to significant T cell activation. Olsutamig is primarily employed in research focused on immuno-oncology, particularly for its potential to selectively induce apoptosis in prostate cancer cells through T cell-mediated mechanisms. -
CD38 Inhibitor
CVN14 is a selective and potent inhibitor of CD38, exhibiting inhibitory activity with human and mouse IC50 values of 19 nM and 2.4 nM, respectively. This compound binds uncompetitively to CD38, forming a complex with ADPR and subsequently inhibiting its enzymatic activity. CVN14 is suitable for research applications focused on neurodegenerative diseases, providing insights into the role of CD38 in these conditions. -
CD38 Inhibitor
Luteolinidin chloride is a potent inhibitor of CD38, with a Ki value of 11.4 μM, and demonstrates significant antioxidant activity. This compound has shown to protect cardiac tissue from ischemia/reperfusion injury by preserving the functionality of endothelial nitric oxide synthase (eNOS) and preventing endothelial dysfunction. Additionally, Luteolinidin chloride acts as a competitive inhibitor of tyrosinase, with an IC50 of 3.7 μM, effectively blocking melanin production. This makes it a valuable reagent for research in cardiovascular protection and skin pigmentation studies. -
Anti-CD38 mAb/IFNα2b Fusion Protein
Modakafusp alfa is a humanized anti-CD38 IgG4 monoclonal antibody fused with two attenuated interferon-alpha 2b molecules, targeting CD38-expressing cells. It exhibits direct anti-proliferative activity against multiple myeloma cells in vitro and elicits significant and sustained antitumor responses in xenograft tumor models. Additionally, the combination of Modakafusp alfa with anti-PD-1 antibodies promotes immunomodulation and enhances antitumor efficacy, demonstrating a favorable tolerance profile in murine models. This reagent is valuable for research in multiple myeloma therapy and immune checkpoint modulation. -
CD38 Inhibitor
CD38 Inhibitor 2 is a selective inhibitor of CD38 with an IC50 range of 0.01 to 0.1 μM. This compound demonstrates potent inhibition of CD38 enzymatic activity, making it a valuable tool for studies focused on NAD+ metabolism and immune regulation. Its applications extend to cancer research, immunology, and age-related studies, contributing to a better understanding of the role of CD38 in various biological processes. -
CD38 Inhibitor
Ara-F-NAD+ is an arabino analogue of NAD+ and functions as a potent, reversible, and slow-binding inhibitor of CD38 NADase. This compound effectively modulates NAD+ metabolism, making it a valuable tool for studying the role of CD38 in various biological processes. Ara-F-NAD+ has potential applications in research focused on immune regulation, cellular signaling, and metabolic disorders related to NAD+ homeostasis. -
Anti-CD38 Antibody
Sanritatug is a humanized IgG1κ antibody that specifically targets CD38, a cell surface protein involved in immune regulation and metabolism. This antibody has demonstrated significant potential in modulating immune responses and is being investigated for therapeutic applications in various hematological malignancies and autoimmune diseases. Sanritatug may aid in the exploration of CD38's role in disease pathophysiology and the development of targeted immunotherapies. -
CD38 Inhibitor
6-Alkyne-F-araNAD is an irreversible inhibitor of CD38, a critical enzyme involved in the regulation of cyclic ADP-ribose and NAD metabolism. This compound enhances the efficacy of fluorescent probes, such as SR101-F-araNMN, allowing for improved visualization of intracellular CD38 localization. It serves as a valuable tool in studies related to immune signaling and cellular response mechanisms. -
CD38 Hydrolase Inhibitor
CD38-IN-5 is a selective inhibitor of CD38 hydrolase, exhibiting an IC50 of 4.0 μM, while sparing CD38 cyclase activity. This compound is particularly effective in enhancing natural killer (NK) cell-mediated tumor cytotoxicity and promotes increased levels of NADH+ and IFNγ in activated peripheral blood mononuclear cells (PBMCs). CD38-IN-5 serves as a valuable tool for cancer research, facilitating the investigation of immune modulation and tumor interactions. -
CD38 Inhibitor
(E/Z)-CCR-11 is a selective inhibitor of CD38, exhibiting an IC50 value of 20.8 μM against CD38 cyclase. This compound effectively enhances cellular NAD+ levels and promotes the production of interferon γ. It is valuable for research applications focused on cellular metabolism and immune response modulation. -
HA-CD44 Interaction Inhibitor
HA-CD44 Interaction Inhibitor 2 is an inhibitor that targets the interaction between Hyaluronic acid (HA) and CD44. It exhibits antiproliferative effects on CD44-positive cancer cells, effectively disrupting cancer sphere integrity and decreasing cell viability in a dose-dependent manner. This compound is suitable for applications in tumor research aimed at understanding the role of CD44 in cancer progression. -
HA-CD44 Interaction Inhibitor
HA-CD44 Interaction Inhibitor 1 is a specific inhibitor of the interaction between hyaluronic acid (HA) and CD44. By disrupting this interaction, it demonstrates significant antiproliferative effects on CD44+ cancer cell lines. This compound is valuable for research aimed at understanding cancer progression and potential therapeutic strategies targeting CD44-mediated cellular processes. -
CD47 Inhibitor
Evorpacept is a high-affinity CD47 inhibitor designed to block the CD47-SIRPα immune checkpoint interaction. By binding to CD47, Evorpacept facilitates the inhibition of wild-type SIRPα binding, enhancing immune response against tumors. This reagent is particularly relevant for research applications focused on acute myeloid leukemia and other malignancies where CD47 plays a pivotal role in immune evasion. -
CD47 Fusion Protein
Maplirpacept is a CD47 fusion protein designed to inhibit the CD47 pathway. By binding to CD47, the protein promotes phagocytosis of cancer cells, enhancing the immune response against tumors. This reagent is utilized in research focused on immuno-oncology and the modulation of immune evasion mechanisms in cancer therapy. -
Anti-MS4A1/CD47 Antibody
Amulirafusp alfa is an anti-MS4A1/CD47 IgG1κ type human antibody designed to target the MS4A1/CD47 axis. This antibody exhibits key biological activity by antagonizing CD47-mediated immune evasion, thereby enhancing phagocytosis and promoting anti-tumor immunity. It is suitable for applications in cancer immunotherapy research and studies exploring immune cell interactions in various disease models. -
Anti-CD47 Antibody
TQB-2928 is a monoclonal antibody targeting CD47, a prominent regulator of immune evasion in cancer cells. This reagent plays a crucial role in research focused on cancer immunotherapy by blocking the "don't eat me" signal that CD47 transmits to macrophages. TQB-2928 is essential for studying tumor microenvironments, immune responses, and developing therapeutic strategies aimed at enhancing anti-tumor immunity. -
CD47/SIRPα blocking peptide
Pep-20 is a CD47/SIRPα blocking peptide that inhibits the interaction between CD47 and SIRPα, demonstrating KD values of 2.91 μM for human CD47 and 3.63 μM for mouse CD47. With IC50 values of 24.56 μM and 12.03 μM, respectively, for blocking these interactions, Pep-20 exhibits significant anti-tumor activity. This peptide is useful in research applications focused on immune evasion in cancer therapies and interactions within the tumor microenvironment. -
CD47/SIRPα Blocker
NCGC00138783 free base is a selective blocker of the CD47/SIRPα interaction, exhibiting an IC50 of 50 µM. By inhibiting this axis, NCGC00138783 free base promotes immune cell activation, making it a valuable tool for research in cancer immunotherapy and immune modulation studies. Its ability to disrupt CD47 signaling can facilitate investigations into tumor evasion mechanisms and potential therapeutic strategies. -
CD47 Monoclonal Antibody
AO-176 is a humanized anti-CD47 IgG2 monoclonal antibody that targets the CD47-SIRPα interaction to induce tumor phagocytosis. This antibody preferentially binds to tumor cells over normal cells and promotes tumor cell death through a direct mechanism, independent of antibody-dependent cell-mediated cytotoxicity (ADCC). AO-176 exhibits dose-dependent antitumor effects in tumor xenograft models, making it a valuable tool for cancer research, particularly in studies involving lymphoma. -
CD73 Inhibitor
CD73-IN-5 is a potent and selective small molecule inhibitor of CD73, exhibiting an IC50 value of 19 nM. This compound effectively interferes with the enzymatic activity of CD73, which plays a critical role in the production of adenosine in the tumor microenvironment. CD73-IN-5 is utilized in research applications exploring immunomodulation, cancer therapy, and the therapeutic potential of targeting adenosine signaling pathways. -
CD73 Inhibitor
CD73-IN-4 is a selective inhibitor of CD73, functioning through the blockade of adenosine production. With an IC50 of 2.6 nM against human CD73, it demonstrates significant potency in modulating immunosuppressive signals in the tumor microenvironment. This compound is valuable for investigating cancer immunology and exploring therapeutic strategies aimed at enhancing anti-tumor immune responses. -
CD73 Inhibitor
OP-5244 is a potent and orally active inhibitor of CD73, with an IC50 of 0.25 nM. By blocking adenosine production, OP-5244 effectively reverses immunosuppression, making it a valuable tool in cancer research. Its application can aid in the exploration of therapeutic strategies aimed at enhancing anti-tumor immunity. -
Anti-CD73/TGF-β Antibody
Dalutrafusp alfa is a bifunctional antibody that targets CD73 and TGF-β, key components involved in the immunosuppressive pathway. This compound modulates immune responses by inhibiting adenosine production and blocking TGF-β signaling. It is primarily utilized in research focused on tumor immunology and the modulation of immune checkpoints. Its unique mechanism allows for exploration in various therapeutic applications, particularly in cancer treatment and autoimmune diseases. -
NTPDase1 Inhibitor
8-BuS-AMP is an inhibitor of NTPDase1, CD73, and CD39, demonstrating an IC50 of 35 μM and a Ki of 0.292 μM for human NTPDase1, alongside Ki values of 1.19 μM for CD73 and 0.847 μM for CD39. This compound interacts with the substrate-binding sites of NTPDase1 and CD73, effectively preventing the conversion of ATP and AMP to adenosine, which promotes the activation and proliferation of human peripheral T lymphocytes. 8-BuS-AMP exhibits robust enzymatic hydrolysis resistance and metabolic stability, and it has no activity against P2Y1 and P2Y12 receptors. This reagent is suitable for investigations into purinergic signaling pathways and cancer research. -
CD73 Inhibitor
ORIC-533 is a selective, orally active inhibitor of CD73 that operates through an AMP-competitive mechanism, demonstrating potent inhibition of adenosine production with a sub-nanomolar affinity (Ka 0.03 nM). This compound has shown significant promise in the context of multiple myeloma, as it enhances the cytotoxic activity of the immune system against tumor cells by reversing immunosuppression, inducing immunogenic cell death, and activating various immune cells including dendritic cells, T cells, and NK cells, while exhibiting minimal toxicity to normal cells. Furthermore, combined administration of ORIC-533 with daratumumab effectively increases intratumoral CD8+ T cell infiltration and substantially inhibits tumor growth in preclinical models.
